ClinicalTrials.gg
Active, not recruitingNCT04088396Updated Aug 11, 2026

A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)

A Phase 3 interventional study of Baricitinib and Tocilizumab in Systemic Juvenile Idiopathic Arthritis, sponsored by Eli Lilly and Company. Active, not recruiting at 55 sites in 14 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Arthritis, Juvenile with a site in Italy — 20 open to participants now, 24 under way, 11 of them phase 3. Arthritis, Juvenile · Italy.

Planned enrollment
29th of 43
58 · median 90
Started
2020
with 1 other
Phase 3
28 of 56
9 open now
Primary completion
2026-10
later than 8 of 23 live
Registered
34th of 56
by date
Lead sponsor
4 of 56
Eli Lilly and Company

Among the 56 studies in Arthritis, Juvenile with a site in Italy, this one is the 29th largest by planned enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2020, is one of 28 in phase 3, reaches primary completion later than 8 of the 23 other live ones, and was the 34th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

20 of the 56 studies in Arthritis, Juvenile with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Arthritis, Juvenile with a site in Italy, or all of them as a file.
02

Study summary

The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.

03

Conditions studied

  • Systemic Juvenile Idiopathic Arthritis

Keywords

  • Systemic
  • Fever
  • Flare
  • sJIA
  • JIA
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a diagnosis of systemic Juvenile Idiopathic Arthritis (sJIA) as defined by International League of Associations for Rheumatology (ILAR) criteria with onset before the age of 16 years
  • Participants must have at least 2 active joints at screening and baseline
  • Cohort 1 (IL-6 inhibitor therapy naive): Participants who are at least 1 year and less than 18 years of age, except in countries that restrict use of tocilizumab in participants less than 2 years of age
  • Cohort 2 (open-label baricitinib): Participants who are at least 1 year and less than 18 years of age

Exclusion criteria

Exclusion Criteria:

  • Participants must not have polyarticular JIA (positive or negative for rheumatoid factor), extended oligoarticular JIA, enthesitis-related JIA, or juvenile psoriatic arthritis
  • Participants must not have persistent oligoarticular arthritis as defined by the ILAR criteria
  • Participants must not have a history or presence of any inflammatory condition other than JIA
  • Participants must not have active anterior uveitis or are receiving concurrent treatment for anterior uveitis
  • Participants must not have active fibromyalgia or other chronic pain conditions that, in the investigator's opinion, would make it difficult to appropriately assess disease activity for the purposes of this study
  • Participants must not have biologic features of Macrophage Activation Syndrome (MAS) over the past 12 weeks
  • Participants must not have a current or recent (\<4 weeks prior to baseline) clinically serious infection
  • Participants must not have a positive test for virus
  • Participants must not have evidence of active tuberculosis (TB) or untreated latent TB
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Baricitinib

    Baricitinib given orally.

    Drug: Baricitinib

  • Active comparator
    Cohort 1 Tocilizumab

    Tocilizumab given Subcutaneously (SC).

    Drug: Tocilizumab

  • Experimental
    Cohort 2 Baricitinib

    Baricitinib given orally.

    Drug: Baricitinib

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Adapted Pediatric American College of Rheumatology 30 Responder Index (PediACR30) Response Criteria at Week 12

    Percentage of Participants Achieving Adapted PediACR30 Response Criteria

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving Adapted PediACR30 Response Criteria at Week 24

    Percentage of Participants Achieving Adapted PediACR30 Response Criteria

    Time frame: Week 24

  2. Percentage of Participants with Inactive Disease

    Percentage of Participants with Inactive Disease

    Time frame: Week 12

  3. Percentage of Participants with Minimal Disease Activity

    Percentage of Participants with Minimal Disease Activity

    Time frame: Week 12

  4. Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27

    Change from Baseline in JADAS-27

    Time frame: Baseline, Week 24

  5. Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item

    Change from Baseline in Arthritis-Related Pain Severity as Measured by the CHAQ Pain VAS Item

    Time frame: Baseline, Week 24

  6. Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)

    PK: Cmax, ss of Baricitinib

    Time frame: Baseline through Week 24

  7. PK: Area Under the Baricitinib Concentration-Time Curve at Steady-State (AUC, ss)

    PK: AUC, ss of Baricitinib

    Time frame: Baseline through Week 24

07

Study locations

55 sites
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · www.vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2020 (actual). Primary completion is estimated for Oct 2026, 80 months after the start.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 80 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2019
First posted
Sep 12, 2019
StartActual
Feb 12, 2020
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04088396
Responsible party
Sponsor
First posted
Sep 12, 2019
Start date
Feb 12, 2020
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Aug 11, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion